Todd Kerner
Physical Medicine & Rehabilitation · Dublin, OHNPI 1184845943
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,760 of the $6,595 with a category attached, or 87.3%. 29 manufacturers reported payments, led by AbbVie at 24.8% of the total. 2025 is the largest year on record at $2,122, 3.2 times the $669 reported in 2019. Among physical medicine & rehabilitation clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Abbott$2K
- Pfizer$1K
- Collegium Pharmaceutical, Inc.$389
- Biohaven Pharmaceutical Holding Company Ltd.$362
- Biohaven Pharmaceuticals, Inc.$288
- plus $1K from 23 others
What the payments were for
- Travel & lodging$81912%
- Food & beverage$5,76087%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,635 |
| Abbott | 18 | $1,526 |
| Pfizer | 76 | $1,015 |
| Collegium Pharmaceutical, Inc. | 33 | $389 |
| Biohaven Pharmaceutical Holding Company Ltd. | 28 | $362 |
| Biohaven Pharmaceuticals, Inc. | 17 | $288 |
| Almatica Pharma LLC | 17 | $259 |
| Amgen | 7 | $203 |
| Ipsen Biopharmaceuticals, Inc | 9 | $176 |
| Avanir Pharmaceuticals, Inc. | 7 | $123 |
| Vertex | 4 | $104 |
| Zyla Life Sciences, Inc. | 3 | $58 |
| Novartis | 3 | $54 |
| Alfasigma USA, Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $50 |
| Bioventus LLC | 3 | $47 |
| Merz Pharmaceuticals, LLC | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Saluda Medical Americas, Inc. | 1 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Kaleo, Inc. | 1 | $18 |
| Endo USA, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$810
- ETERNA$420
- NURTEC ODT$125
- QULIPTA$125
How this compares
$6,595 in reported general payments places this provider in the 90th percentile of 332 physical medicine & rehabilitation providers in Ohio.
See all physical medicine & rehabilitation providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 17 | $16,048 |
| Gabapentin | 379 | $5,220 |
| Pregabalin | 161 | $2,910 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 84 | $2,622 |
| Etodolac | 67 | $2,208 |
| Duloxetine Hcl | 65 | $1,332 |
| Clonazepam | 25 | $893 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $890 |
| Tramadol Hcl | 135 | $714 |
| Carisoprodol | 11 | $449 |
| Diclofenac Potassium | 12 | $310 |
| Diclofenac Sodium | 29 | $277 |
| Tizanidine Hcl | 56 | $275 |
| Oxycodone Hcl | 15 | $226 |
| Sucralfate | 14 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $1,635 | $16,04817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 332 physical medicine & rehabilitation providers in Ohio.
Other physical medicine & rehabilitation in Dublin
- Francesco SammartinoDublin$32K
- Adam AbrahamDublin$7K
- Amanda OlneyDublin$2K
- Michael BariaLewis Center$175K
- Kathryn MosherAkron$121K
- Marc OrlandoCincinnati$114K
- Aileen PadillaPerrysburg$73K
- Jeffrey StrakowskiColumbus$59K
- Kurt KuhlmanLima$46K
- Francois BethouxCleveland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.